Report finds 70% spike in advanced therapy Phase I trials in UK
Last year saw a 70% rise in Phase I advanced therapy medicinal product (ATMP) studies across the UK clinical trials…
All articles by Joshua Silverwood
Joshua Silverwood
-
-
Boston Scientific sees success in PFA device trial
US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal…
-
Concept Medical enrols first patient in balloon angioplasty trial
Florida healthtech firm Concept Medical has enrolled the first patient in its MAGICAL trial examining its sirolimus-coated balloon against traditional…
-
Boehringer Ingelheim announces Phase III schizophrenia failures
German healthcare giant Boehringer Ingelheim has announced that its drug iclepertin, designed for patients living with cognitive impairment as a…
-
European supergroup launches to tackle diversity in clinical trials
A new pan-European initiative aimed at creating a new less fragmented and more democratic ecosystem for clinical trials across the…
-
OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients
OS Therapies’s HER2-immunotherapy met the primary endpoint in a Phase IIb trial in patients with recurrent, fully resected, lung metastatic…
-
Zai Labs announces positive results in China arm of Phase III cervical cancer trial
Chinese-American biopharmaceutical company Zai Lab has announced positive topline results from the China-specific arm in its Phase III innovaTV-301 study…
-
Sling Therapeutics sees success reducing eye bulge in Phase IIb/III trial
Michigan late-stage biopharma, Sling Therapeutics, said a Phase IIb/III LIDS trial of its oral small molecule therapy designed to treat…
-
Alleviant Medical secures $90m to launch pivotal aortic stent trial
Texas medical device firm Alleviant Medical has secured $90m to fund a second pivotal trial of the company’s heart system…
-
BlueRock accelerates Parkinson’s disease therapy to Phase III
US-based Bayer subsidiary BlueRock Therapeutics has accelerated bemdaneprocel, its investigational cell therapy candidate for Parkinson’s disease, to Phase III trials…